Oral Transmucosal Drugs Market Trends

Advancements in drug delivery technologies have revolutionized the field of medicine, offering more efficient and targeted ways to administer medications.

• PLGA (poly lactic-co-glycolic acid) enhancers in implantable drug delivery systems (IDDS), represent a novel drug delivery systems technology, offering enhanced drug delivery capabilities. PLGA/PEG blend microparticles have been developed to serve as delivery enhancers in implantable drug delivery systems. These microparticles enable the controlled and sustained release of therapeutic agents, enhancing the efficacy and precision of drug delivery within the body, as a result increases the demand of oral transmucosal drugs.
  
• Additionally, needle-free drug delivery technologies are gaining traction, offering alternatives to traditional injections. Companies like PharmaJet and NovaXS are pioneering needle-free systems for vaccine and therapeutic delivery. For instance, the Biojector 2000 is a professional-grade needle-free injection system designed for healthcare providers, capable of delivering intramuscular, subcutaneous, and intradermal injections. Such technological advancements are gaining the attention of healthcare professionals resulting in its increasing demand in the market.